Research programme: metabolic disorders therapy - Biovitrum/Pharmacopeia
Latest Information Update: 18 Mar 2009
At a glance
- Originator Biovitrum; Pharmacopeia Drug Discovery
- Developer Biovitrum; Pharmacopeia
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Metabolic disorders
Most Recent Events
- 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
- 14 Mar 2007 Preclinical development is ongoing
- 29 Oct 2004 Preclinical trials in Metabolic disorders in Sweden (unspecified route)